(P056) VATS With HDR Intraoperative Brachytherapy for Chest Wall Tumors

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

To report on the Roswell Park Cancer Institute experience with iridium-192 high-dose-rate (HDR) intraoperative brachytherapy (IOBT) in minimally invasive, video-assisted thorascopic surgery (VATS) for localized pulmonary malignancy involving the chest wall.

Daniel J. Bourgeois, MD, MPH, Jorge Gomez, MD, Todd Demmy, MD; Roswell Park Cancer Institute

Purpose: To report on the Roswell Park Cancer Institute experience with iridium-192 high-dose-rate (HDR) intraoperative brachytherapy (IOBT) in minimally invasive, video-assisted thorascopic surgery (VATS) for localized pulmonary malignancy involving the chest wall.

Materials and Methods: Five patients in 2012–2013 with node-negative thoracic malignancies involving the chest wall were chosen and consented for pulmonary resections with HDR-IOBT to their chest wall disease via VATS. After completion of the wedge resection, lobectomy, or pneumonectomy, a MicroSelectron HDR unit (model digital V3, Elekta Inc) was used for dose delivery in a specially designed, shielded operating room (OR). This unit uses a 10-Curie (Ci) miniaturized Ir-192 source 1 mm in diameter and around 5 mm in length. The actual treatment plans were generated on the Oncentra Treatment planning system within the OR itself, utilizing the standard geometry treatment plan library generated for various configurations for the Freiburg applicator. The number of catheters, active dwell position along each catheter, prescription depth, and dose prescription were customized based on clinical needs.

Results: Four of the lesions treated were adenocarcinoma (T3N0–IIB), and the fifth was a sarcomatoid carcinoma. One of the patients, with non–small-cell lung cancer, required conversion to open thoracotomy; therefore, the remaining four cases are the focus of this report. All patients received and tolerated treatment without complications. However, the patient with sarcomatoid carcinoma died with brain metastasis within 1 month after the procedure. The patients with adenocarcinoma each received adjuvant chemotherapy, as tolerated, and remain in follow-up with no evidence of disease on surveillance imaging (median follow-up = 4 mo).

Conclusions: HDR-IOBT with Ir-192 via VATS is a technically feasible, well-tolerated procedure for intrathoracic disease involving the pleura and/or chest wall. Further follow-up and larger case population will speak to the efficacy and durability of this procedure, as well as indicate whether larger, analytic trials are appropriate. Laparoscopic images and media are provided.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Related Content